Systematic review: incidence of abdominal/pelvic surgery amongst patients using tegaserod in randomized controlled trials
dc.contributor.author | Schoenfeld, Philip S. | en_US |
dc.date.accessioned | 2010-06-01T18:33:24Z | |
dc.date.available | 2010-06-01T18:33:24Z | |
dc.date.issued | 2004-02 | en_US |
dc.identifier.citation | Schoenfeld, P. (2004). "Systematic review: incidence of abdominal/pelvic surgery amongst patients using tegaserod in randomized controlled trials." Alimentary Pharmacology & Therapeutics 19(3): 263-269. <http://hdl.handle.net/2027.42/71762> | en_US |
dc.identifier.issn | 0269-2813 | en_US |
dc.identifier.issn | 1365-2036 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/71762 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=14984372&dopt=citation | en_US |
dc.description.abstract | Background : In the USA, tegaserod is contraindicated in patients with a history of bowel obstruction, abdominal adhesions or symptomatic gall-bladder disease due to a non-significant difference in abdominal surgery between tegaserod-using and placebo-using patients in Phase III trials. Aim : To calculate the incidence of abdominal and pelvic surgery in tegaserod-using and placebo-using patients in randomized controlled trials and to assess the possible association between medication and surgery, using pre-specified criteria in a blind adjudication procedure. Methods : Primary study selection criteria included: (i) randomized controlled trial; (ii) comparison of tegaserod vs. placebo; and (iii) results reporting the incidence of abdominal and pelvic surgery. A panel of experts in epidemiology and functional bowel disorders reviewed the history of each patient who underwent surgery. Experts were blind with regard to whether patients used tegaserod or placebo. Using pre-specified criteria, experts rated the likelihood of an association between medication use and surgery. Results : Thirteen randomized controlled trials ( n =9857 patients) met the primary study selection criteria. No significant difference in the incidence of abdominal/pelvic surgery was identified between tegaserod-using and placebo-using patients: pelvic surgery, 0.16% vs. 0.19% ( P = 0.80); abdominal surgery (non-cholecystectomy), 0.15% vs. 0.19% ( P = 0.61); cholecystectomy, 0.13% vs. 0.03% ( P = 0.17); total abdominal/pelvic surgery, 0.44% vs. 0.41% ( P = 1.00). Post-adjudication, there was no significant difference in the incidence of abdominal/pelvic surgery between tegaserod-using and placebo-using patients. Conclusion : Data from randomized controlled trials demonstrate a similar incidence of abdominal/pelvic surgery in tegaserod-using and placebo-using patients. | en_US |
dc.format.extent | 70986 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Science Ltd | en_US |
dc.rights | 2004 Blackwell Publishing Ltd | en_US |
dc.title | Systematic review: incidence of abdominal/pelvic surgery amongst patients using tegaserod in randomized controlled trials | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Otolaryngology | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.identifier.pmid | 14984372 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/71762/1/j.1365-2036.2004.01864.x.pdf | |
dc.identifier.doi | 10.1111/j.1365-2036.2004.01864.x | en_US |
dc.identifier.source | Alimentary Pharmacology & Therapeutics | en_US |
dc.identifier.citedreference | Zimmermann AE. Tegaserod — A 5-HT 4 agonist for women with constipation-predominant irritable bowel syndrome. Hosp Formulary 2002; 37: 449. | en_US |
dc.identifier.citedreference | Degen L, Matzinger D, Merz M, et al. Tegaserod, a 5-HT 4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001; 15: 1745 – 51. | en_US |
dc.identifier.citedreference | Coffin B, Farmachidi JP, Rueegg P, Bastie A, Bouhassira D. Tegaserod, a 5-HT 4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Aliment Pharmacol Ther 2003; 17: 577 – 86. | en_US |
dc.identifier.citedreference | Schoenfeld P, Chey WD, Drossman D, et al. Effectiveness and safety of tegaserod in treatment of irritable bowel syndrome: a meta-analysis of randomized controlled trials. Gastroenterology 2002; 122: A1486(Abstract ). | en_US |
dc.identifier.citedreference | Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT 4 partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001; 15: 1655 – 66. | en_US |
dc.identifier.citedreference | Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002; 16: 1877 – 88. | en_US |
dc.identifier.citedreference | Kellow J, Lee OY, Chang FY, et al. An Asia-Pacific, double-blind, placebo-controlled, randomised study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003; 52: 671 – 6. | en_US |
dc.identifier.citedreference | Cohen Munoz V. Relapse of symptoms following withdrawal of tegaserod treatment in irritable bowel syndrome with constipation (IBS-C) (Abstract). Gastroenterology 2003; 124: T1804. | en_US |
dc.identifier.citedreference | Lin S, Zhou L, Xinguang L, et al. Tegaserod provides rapid, effective relief of abdominal pain/discomfort, bloating and constipation in Chinese patients with irritable bowel syndrome with constipation (Abstract). Gastroenterology 2003; 124: S1017. | en_US |
dc.identifier.citedreference | Nyhlin H, Bang C, Elsborg L, et al. Tegaserod is an effective and safe therapy for irritable bowel syndrome in a Nordic population (Abstract). Gastroenterology 2003; 124: M1645. | en_US |
dc.identifier.citedreference | Wald A, Johanson J, Tougas G, et al. Safety and tolerability of tegaserod in patients treated for chronic constipation (CC): a 12-week, double-blind, placebo-controlled multicenter study performed in the Americas (Abstract). Gastroenterology 2003; 124: T1818. | en_US |
dc.identifier.citedreference | Talley N, Kamm M, Mueller-Lissner S, et al. Tegaserod is effective in relieving the multiple symptoms of constipation: results from a 12-week multinational study in patients with chronic constipation. Am J Gastroenterol 2003; 98: A810(Abstract ). | en_US |
dc.identifier.citedreference | 13 Functional Dyspepsia Study D2201. Data on File. East Hanover: Novartis Pharmaceuticals Corporation, 2002. | en_US |
dc.identifier.citedreference | 14 Functional Dyspepsia Study D2202. Data on File. East Hanover: Novartis Pharmaceuticals Corporation, 2002. | en_US |
dc.identifier.citedreference | 15 Functional Dyspepsia Study D2203. Data on File. East Hanover: Novartis Pharmaceuticals Corporation, 2002. | en_US |
dc.identifier.citedreference | Tack J, Delia T, Ligozio G, Sue S, Lefkowitz M, Vandeplassche L. A phase II placebo controlled randomized trial with tegaserod (T) in functional dyspepsia (FD) patients with normal gastric emptying (NGE). Gastroenterology 2002; 122: A154(Abstract ). | en_US |
dc.identifier.citedreference | Camilleri M. Review article: tegaserod. Aliment Pharmacol Ther 2001; 15: 277 – 89. | en_US |
dc.identifier.citedreference | Hasler WL, Schoenfeld P. Incidence of abdominal-pelvic surgery among patients with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther 2003; 17: 997 – 1006. | en_US |
dc.identifier.citedreference | Fisher R, Thistle J, Lembo A, et al. What is the impact of tegaserod on gallbladder emptying? Am J Gastroenterol 2003; 98: A813(Abstract ). | en_US |
dc.identifier.citedreference | Hasler W, Schoenfeld P. Safety profile of tegaserod, a 5-HT4 receptor agonist, for the treatment of irritable bowel syndrome. Drug Safety 2003 in press. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.